Communiqués BiomX Inc.

Actions

PHGE

US09090D1037

Temps Différé Nyse Autres places de cotation 20:21:18 07/06/2024			Varia. 5j.	Varia. 1 janv.
0,355 ^USD	-4,08 %		-11,25 %	+26,79 %

21/05	Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024
20/05	BiomX Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers	03/06	AQ
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards	30/05	GL
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards	30/05	AQ
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024	30/05	GL
BiomX : Introduction	21/05	PU
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates	21/05	GL
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024	15/05	GL
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases	24/04	AQ
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)	23/04	AQ
BiomX Announces the Appointment of Susan Blum to its Board of Directors	18/04	AQ
BiomX : Introduction	04/04	PU
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure	04/04	AQ
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	03/04	AQ
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024	27/03	AQ
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing	18/03	AQ
BiomX : Material Agreement - Form 8-K	06/03	PU
BiomX : Introduction	06/03	PU
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing	06/03	AQ
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis	04/01	AQ
BiomX : CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 CONTENTS - Form 8-K	07/12	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BiomX Inc.

Actions

PHGE

US09090D1037

Communiqués

Filtres